Newswire (Published: Tuesday, June 6, 2017, Received: Thursday, June 1, 2017, 10:14:43 PM CDT)

Word Count: 464

Recent Findings from University of Pennsylvania School of Medicine Has Provided New Data on Prostate-Specific Antigen (Association between features of patient-provider discussions and routine prostate-specific antigen testing)

By a News Reporter-Staff News Editor at Life Science Weekly -- Current study results on Enzymes and Coenzymes - Prostate-Specific Antigen have been published. According to news originating from Philadelphia, Pennsylvania, by NewsRx correspondents, research stated, "Although the US Preventive Services Task Force recommends against routine prostate cancer screening with prostate-specific antigen (PSA) testing, specialty organizations support screening via shared decision making between providers and selected patients. While discussions about advantages and disadvantages of testing are a feature of patient-centered care, it is unclear how provider recommendations and the presence of a personal doctor influence testing in the presence of such discussions."

Our news journalists obtained a quote from the research from the University of Pennsylvania School of Medicine, "We used the 2013 Behavioral Risk Factor Surveillance System to identify 1,737 male respondents surveyed about their PSA testing decisions. We describe the prevalence of provider recommendations and utilize weighted multivariable logistic regression models to examine the impact of provider recommendations and presence of a personal doctor on routine testing while accounting for patient-provider discussions about advantages and disadvantages. The majority (70.4%) of respondents reported some form of discussion with providers about testing and most underwent screening in accordance with provider recommendations. In multivariable analyses, men whose providers had never recommended PSA test were less likely to receive screening [OR 0.03, 95% CI (0.02-0.05)], and patients who did not identify a personal doctor in their care were less likely to undergo testing [OR 0.12, 95% CI (0.04-0.32)]. Provider recommendations and having a personal doctor are associated with routine PSA testing."

According to the news editors, the research concluded: "These findings suggest that providers and policymakers should be aware of how the content and context of communication with patients, beyond discussions of risks and benefits, can influence routine PSA testing behaviors."

For more information on this research see: Association between features of patient-provider discussions and routine prostate-specific antigen testing. Plos One, 2017;12(5):e0177687. (Public Library of Science - www.plos.org; Plos One - www.plosone.org)

The news correspondents report that additional information may be obtained from J.M. Liao, Division of General Internal Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, United States. Additional authors for this research include M.J. Ommerborn and C.R Clark (see also Enzymes and Coenzymes - Prostate-Specific Antigen).

Keywords for this news article include: Kallikreins, Philadelphia, Pennsylvania, United States, Endopeptidases, Serine Proteases, Peptide Hydrolases, Enzymes and Coenzymes, North and Central America, Prostate Specific Antigen, Prostate-Specific Antigen.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

Public Library of Science

Places

Central America
North America
United States
Americas
Pennsylvania
Philadelphia

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
Life and Society
      Education